Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ628630,50,16
KB768771-0,77
PKN78,478,48-3,54
Msft-0,56
Nokia4,3364,3515-0,90
IBM-1,70
Daimler AG76,9877,01-3,00
PFE-1,70
19.06.2021 2:04:00
Indexy online
AD Index online
select
AD Index online
 

BioAlliance
Poslední obchod Změna (%) Změna Objem obchodů ()
- - -
Poslední obchod Změna (%) Změna Objem obchodů ()
- - -
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 20.06.2021
Popis společnosti
Obecné informace
Název společnostiOnxeo SA
TickerALONX
Kmenové akcie:Ordinary Shares
RICALONX.PA
ISINFR0010095596
Poslední známé roční výsledky31.12.2020
Poslední známé čtvrtletní výsledky31.12.2020
Počet zaměstnanců k 31.12.2020 25
Akcie v oběhu k 17.03.2021 91 137 452
MěnaEUR
Kontaktní informace
Ulice49 boulevard du General Martial Valin
MěstoPARIS
PSČ75015
ZeměFrance
Kontatní osoba 
Funkce kontaktní osoby 
Telefon33 145 587 600
Fax33145580881

Business Summary: Onxeo SA, formerly Bioalliance Pharma SA, is a France-based biopharmaceutical company. In July 2014, the Company, as the continuing entity, merged with Topotarget AS creating Onxeo, a company dedicated to orphan oncology diseases. Onxeo aims at holding a portfolio of advanced programs targeting severe pathologies with unmet clinical needs. It has two programs in clinical development stage: Livatag, a doxorubicin Transdrag in Phase III, for the treatment of primary liver cancer, and Validive, a clonidine Lauriad in Phase II, for treatment of radio/chemo-induced severe oral mucositis at patients with head and neck cancer. It also has one registered product in the United States, Beleodaq/ belinostat, for the treatment of peripheral T-Cell lymphoma (PTCL) and opportunities for further development; and two initial drugs registered in Europe and the United States: Loramyc/ Oravig for the treatment of oropharyngeal candidiasis, and Sitavig for the treatment of recurring herpes labialis.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2020, Onxeo SArevenues decreased 59% to EUR1.8M. Net income applicable tocommon stockholders totaled EUR1.1M vs. loss of EUR33.7M.Revenues reflect Oncology products segment decrease of 69%to EUR1.1M, Other products segment decrease of 9% toEUR693K, Rest of the World segment decrease of 58% toEUR1.3M, France segment decrease of 64% to EUR302K.
Odvětvová klasifikace
TRBC2012Pharmaceuticals (NEC)
RBSS2004Pharmaceuticals - Diversified
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Research and Development in Biotechnology
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICPharmaceutical Preparations
SICCommercial Physical Research



  • Poslední aktualizace: 20.06.2021
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chief Executive Officer, Member of the Executive Committee, Member of the BoardJudith Greciet4429.06.201102.03.2011
Vice President, Chief Financial Officer, Member of the Executive CommitteeNicolas Fellman41
Executive Vice President and Chief of U.S. OperationsPhilippe Maitre5921.03.201621.03.2016
Chief Scientific Officer, Member of the Executive CommitteeFrancoise Bono-01.03.201701.03.2017
Vice President Quality Qualified Person and Member of the Executive CommitteeMichel Forest-
Vice President, Head of Research & DevelopmentLouis Kayitalire-
Director of Legal Affairs, Agreements and Licensing, Member of the Executive CommitteeAude Michel-01.01.2008
Director of Human Resources, Member of the Executive CommitteeAudrey Legentil-Dumery-10.02.201510.02.2015
Director of Alliance Management, Member of the Executive CommitteeElisabeth Carstensen4410.02.201510.02.2015
Chief Medical Officer, Member of the Executive CommitteeOlivier de Beaumont-01.03.201701.03.2017